01 / DESIGN
What was studied?
The trial randomized 529 participants with heart failure with preserved ejection fraction and obesity to semaglutide or placebo for 52 weeks.
02 / FINDINGS
What did the researchers report?
The semaglutide group had greater improvement in a heart-failure symptom score, greater weight reduction and better six-minute walk performance than the placebo group.
03 / LIMITS
How should it be interpreted?
The primary endpoints were symptoms and weight, not proof of longer survival. Results in this particular heart-failure population cannot be extended automatically to other forms of heart failure or to healthy individuals.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.